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In late 1963, we were led and stimulated in a new direction by Dr Keith Reemtsma. 
I am here mainly to pay tribute to Reemtsma's remarkable feat of 25 years ago. It 
was an experience and an accomplishment which as the years have gone by has as-
sumed an even greater significance than at that time. I have confidently predicted, 
as has Keith in an indirect way, that the magnitude of the accomplishment will be-
come even greater in the years ahead because like Keith, I am convinced that animal 
to human transplantation is close to the horizon. The main reason to believe this is 
how close efforts at both chimpanzee-to-human and baboon-to-human transplanta-
tion came to succeeding in that now distant time. However, failure to complete the 
task over a span of 25 years introduces a note of very real caution because the inabil-
ity to exploit this kind of breakthrough generally means that the problem is deeper 
and more unfathomable than was actually appreciated. 
Baboon renal heterotransplantation 
Our studies with baboon-to-human renal heterotransplantation were done at the 
University of Colorado in 1963. Some of the people who are here today came to 
Denver in 1963 and have now resurfaced as handsome as ever, Dr Moor-Jankowski 
being included. The participants in these studies brought to the University of Colora-
do an international group. Of that group, Professor K.A. Porter of St. Mary's Hospi-
tal and Medical School may have been the single most important contributor because 
of what he did, and was able to do, thanks in part to the generosity of Dr Reemtsma. 
Correspondence to: Thomas E. Starzl. M.D., Ph.D., Department of Surgery, 360 I Fifth A venue, Falk Clin-
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Fig. I. (Above) Preparation ofheterografts. A, complete midline incision; B, method used to cold perfuse 
the heterograft complex; C, in situ perfusion: D, the heterograft after removal. (Opposite) Insertion of 
Reemtsma gave Porter pathology material from the chimpanzee-to-human hetero-
transplants and Porter was then able to study the pathology with three species of 
heterograft donors. These were the Rhesus monkey which Keith did not mention, 
the chimpanzee which was the best donor and, in between these in biological desira-
bility, the baboon. A kind of comparative pathology spectrum was laid out by a sin-
gle world class pathologist. 
The surgical techniques were similar in Reemtsma's chimpanzee heterotransplan-
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heterografts after technique of Reemtsma. E, anastomosis of distal aorta and vena cava to external iliac 
vessels. F, parallel ureteroneocystostomies; G, folding back of kidneys in ordcr to occupy less space. With 
permission. From Ref. 3. 
tations and in our work with baboons. The operation was immortalized by Jean 
McConnell's drawings which were published in 1964 [1]. In the caption to these draw-
ings, we credited this operation to Dr Reemtsma (Fig. 1). This so-called lollipop kid-
ney technique which Dr Reemtsma first used in the chimps came into common use 
for the transplantation of pediatric kidneys and is widely used today. Thus, the oper-
ation developed a life of its own apart from its role in heterotransplantation. 
The six baboon heterotransplantations were thoroughly described in the literature 
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TABLE! 
Heterotransplantation of baboon kidneysa 
Duration of function 
CCr at one day 
aRaw data in Refs. I and 3. 
10--60 days (mean 36) 
34-61 ml/min (mean 46.3) 
of the time [1-3]. In some of the cases, single baboon kidneys were placed into the 
adult human and in others double kidneys were used. The organs functioned for 
10-60 days, mean 36 (Table I), and that allowed liberation from dialysis for this peri-
od of time. 
This means of course that none of these kidneys underwent hyperacute rejection. 
The creatinine clearance after I day was 34-61 mljmin or for a mean of 46 (Table 
I). That was about half of what one could expect with a homograft as I will show 
you with direct comparison in just a moment. 
Moor-Jankowski had determined the blood types of these baboons [4]. In 1963, 
it was thought that the baboon had only blood types A, Band AB. In half of the 
recipients there was a confrontation of the ABO blood group barriers, 2 AB to 0 
and 1 B to 0 (Table II). These three grafts functioned for 10, 49 and 25 days. The 
other three grafts were ABO compatible. These kidneys survived for 23, 49 and 60 
days. Blood group compatibility was thought to be a favorable condition at the time 
because it was in 1963 that we had delineated for the first time the rules of ABO 
matching. The events of this discovery are summarized elsewhere [5]. We showed in 
human recipients of renal homografts that hyperacute rejection could be caused by 
ABO incompatibilities, and we provided evidence that preformed antigraft isoagglu-
tinins wcre responsible. Incidentally, I should mention that the expression of ABO 
antigens in baboons is faint so that the animals were difficult to type. Typing was 
done by Moor-Jankowski with salivary collections. The poor representation of ABO 
antigens in tissues might have explained the non-effect of blood group incompatibi-
lity. 
TABLE II 
ABO blood types 
n Days of function 
AB 0 2 10, 49 
B 0 I 25 
A A 23 
B B 49 
B AB 60 
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Tn Fig. 2 is shown the course of one of the baboon heterograft recipients. This 
young man was discharged from the hospital 30 days after receiving a baboon hetero-
graft. Eventually. the baboon kidneys were removed because the recipient was sick 
even though the heterograft still had life-supporting renal function with urine urea 
concentration of about 500 mg%. A homograft now was found and was transplanted 
on the same day as heterograft removal. The homograft doubled the urine urea con-
centration. The creatinine clearances were in the 40-50 ml/min range throughout 
most of the residence of the heterograft and were still about 20 mllmin on the day 
the heterograft was removed. The creatinine clearance of the homograft was 100 mIl 
min immediately. Eventually the patient died of sepsis after 40 more days with a total 
survival of more than 100 days. The important observation was the astonishing per-
formance of an animal heterograft for 2 months in a human. 
The baboon kidneys were sent to Porter who demonstrated cell mediated rejection. 
~b 
(filgiIIl day) 
FiK. 2. Patient SD 3. Recipient was AB + blood group. and donor was B. The patient was anuric preopera-
tively. The difference in quality of function of the hetcrografts, compared to the secondarily placed homo-
grafts. is evident. Heterotransplant rejection crises occurred after five and 50 days. Urine function contin-
ued until heterografts were removed. With permission. From Ref. 3. 
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The ceJJ composition of the infiltrate was no different than in homograft rejection, 
and Porter told us that he could not really say from histopathological examination 
that this was a heterograft after some 2 months in residence. However, these kidneys 
had the infarcts , cortical and subcortical (Fig. 3), which have come to be associated 
with vascular lesions of humoral antibody rejection. With such infarcts comes sepsis. 
With special stains, Porter showed widespread vascular lesions in the baboon hete-
rografts. There is nothing specific about these lesions. They are also found in homo-
grafts. In fact, the homograft that was eventually retrieved at autopsy from the pa-
tient whose course is shown in Fig. 2 had the same vascular lesions as were in the 
preceding heterografts. 
As [ went back over these papers [1-3] in preparation for this talk , I wondered 
why there were not better humoral antibody studies in these patients. I soon remem-
bered that cytotoxic antibodies as a cause for humoral rejection were not recognized 
by Terasaki until more than a year later [6]. In 1963, we were working with antibody 
systems that mayor may not have been really relevant to the problem of humoral 
rejection. Figure 4 summarizes observations in one of those patients who received 
an ABO incompatible kidney showing anti-A and anti-B isoagglutinins, as well as 
heterospecific hemagglutinins. After placement of the heterograft, both ABO isoag-
glutinins and the heterospecific hemagglutinins declined, indicating that there was 
antibody binding to the transplant. Electronmicrographic studies were confirmatory. 
Tn contrast, with an A-to-A transplant the isoagglutinins were not altered during the 
Fig. 3. Heterografts removed from patient whose course is shown in Fig. 2. 
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Fig. 4. Serial measurements of the activities of anti-A and anti-B hemagglutinins and heteroagglutinins 
of Patient SD 5, type 0, following transplantation of the kidneys from a type AB baboon. Note that the 
antibody titers rose after the patient became anuric during the second rejection episode. With permission. 
From Ref. 3. 
postoperative course, but the heterohemagglutinins which were present in everyone 
of these human recipients fell as if they were being screened out by the grafts (Fig. 
5). 
So much for the baboon studies. The death of six patients was a devastating loss. 
We never tried again. Porter's conclusions were as follows after comparing the ba-
boon kidneys to transplants of Rhesus monkeys and chimpanzees [3]. 
"On the basis of present information, which is admittedly rather scant, it would appear 
that a treated chimpanzee renal heterotransplant fares no worse in the early stages than 
a treated human renal homotransplant from an unrelated donor. It is clear, however, 
that baboon heterotransplants, and particularly Rhesus monkey transplants, invoke a 
fierce response on the part of the host despite any treatment that is available at present. 
In the resulting rejection process, cellular infiltration and peritubular capillary destruc-
tion are prominent early features, but by nine days the vasculonecrotic element is 
marked. There is some circumstantial evidence to suggest that, whereas the peritubular 
capillary damage is mediated by cell-bound antibody, the fibrinoid necrotic vascular le-
sions are caused by circulating antibody." 
Porter's comment about antibodies was prophetic. The humoral component of rejec-
tion has been the central topic for any discussion of heterotransplantation between 
divergent species since that time. In fact, xenograft models have been used to evaluate 
treatment of hyperacute rejection with the assumption that the mechanisms of de-
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Fig. 5. Serial measurements of the anti-B hemagglutinin and heteroagglutinin activities in Patient SO 1, 
blood group A, following transplantation of kidneys from a type A baboon. With permission. From Ref. 3. 
struction of xenografts are the same as hyperacute rejection of homo grafts in sensit-
ized recipients. Such techniques to prevent humoral rejection have been summarized 
elsewhere [5]. Those include plasmapheresis; antibody removal with a Staph A col-
umn; transplantation of serial grafts to reduce the antibody titer; infusion of the che-
lating agent and anticoagulant, citrate, which also is a very effective way of prevent-
ing complement activation; and as described elsewhere in these proceedings by 
Makowka the use of prostanoids and inhibitors of the inflammatory response. All 
of these treatment protocols were tried in dogs which were given pig kidney grafts. 
There was prolongation of survival from a few minutes in untreated dogs to several 
hours in animals treated with the various methods [5]. However, getting beyond the 
several hours of prolongation before the supervention of hyperacute rejection has 
really confounded investigators to this day. 
Chimpanzee liver heterografts 
Before closing, I want to mention three chimpanzee-to-human orthotopic liver grafts. 
These were important cases, also done in the dark ages when we had primitive im-
munosuppression by today's standards. Yet here also there was near success. The 
first patient was a child with biliary atresia. After operation, the bilirubin fell to nor-
mal and stayed there until death from sepsis (Fig. 6). In commenting in 1969 about 
this chimpanzee-to-human heterograft Porter said that he could not distinguish the 
changes from those in homografts. His exact words were [8]: 
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Fig. 0. The course of a child with intrahepatic biliary atresia who received an orthotopic chimpanzee hete-
rograft on July 15, 1966. ALG was started two weeks in advance of operation. The 50 R indicates local 
homograft irradiation. With permission. From Ref. 7. 
"The histologic changes in this liver heterograft were very like those that occur in hepat-
ic homografts. The lymphoid cell infiltration in the portal tracts was dense, but no more 
so than in the grafts from patients OT7-to-1O and in many treated canine hepatic homo-
grafts. There were no lesions of large blood vessels. Fibrinoid necrosis of arterial walls 
was conspicuously absent. It was difficult to believe that this child's death had been the 
direct result of hepatic failure produced by rejection. The analysis of the postoperative 
clinical events given in Chapter Nineteen tended to support the conclusion that consid-
erable liver function was maintained until almost the end of life." 
We have had experience with two other liver heterotransplantations. Although I re-
ported them, I may have tried subconsciously to hide the experience by stashing the 
reports in obscure corners and funny places. Hugh Auchincloss smoked me out by 
some marvellous detective work in his review of heterotransplantation which was 
published recently [9]. Much to my amazement (possibly even chagrin), Auchinc10ss 
had discovered all of these cases with one exception. Table III presents a summary 
of these orthotopic liver heterotransplantations. The dates of the operations were in 
1966, 1969 and 1973. The first heterograft was the one which I have already men-
tioned [7, 8]. The second heterograft may have been hyperacutely rejected [10]. There 
were many dumb things that were done in this case, and some are mentioned in Table 
III. One thing which I wanted to point out is that Fritz Bach, who is a participant 
at these Proceedings, studied many chimpanzees with MLC and found two potential 
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TABLE III 
Chimpanzee-to-human liver transplantation 
Recipient age 
28 months 
7 months 
23 months 
Date 
15 July 1966 
3 December 
1969a,b,c 
9 June 1973 
aPositive cytotoxic crossmatch, 
bMLC donor selection (F, Bach), 
'Kidneys placed first to deplete antibodies, 
Days graft function 
9 
0 
14 
Pathology Refs, 
Like homograft 7,8 
Normal 10 
No rejection; cen- II 
trilobular chole-
stasis, was a re-
transplant 
donors out of a collection of many at the Holloman Air Force Base, Alamogordo, 
New Mexico, that provoked relatively little reaction by the lymphocytes of the recipi-
ent. Unfortunately, this child was studied so exhaustively that transfusions were re-
quired to replace blood drawn and by the time the child was transplanted, there was 
a positive cytotoxic crossmatch with the chimp donor. We made another foolish mis-
take at operation when we actually heparinized this child after the liver was put in. 
The child bled to death. The liver one day later was normal [10]. 
T operated on the third patient on 9 June 1973 and had a description of the case 
in a paper honoring the late Dave Hume in 1974 at his memorial service in Richmond 
(addressed to Dr Hugh Auchincloss for his records). Very complete data about this 
last case was given, but this is not mentioned in the title of my article [11]. The recipi-
ent was 23 months old. The heterotransplantation was performed under desperate 
circumstances. Ten days previously, this child had received a homograft which we 
thought might have been hyperacutely rejected because there was a powerful cytotox-
ic crossmatch with the original human donor. The chimpanzee liver was placed into 
the dying child in replacement of the homograft, and it functioned for 14 days. This 
child died of sepsis in the same way as had occurred in the 1966 patient. There was 
no rejection, although there was some centrilobular cholestasis. This liver was in 
amazingly good shape and, in retrospect, one has to really wonder, because of the 
troubles we were having with biliary tract reconstruction until a year or so after that, 
if there may not have been a technical component. 
Future prospects 
Over the years, we have had a lively interest in the humoral component of what we 
perceive to be a double-edged problem, that is control of cellular immunity and more 
---------~K~K-~K-K-.. -
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importantly of humoral immunity. The prospect of a genuine breakthrough in con-
trolling preformed heterospecific antibodies has been bleak, and I do not see a solu-
tion to this problem in the near future. Perhaps the work that Makowka and the 
group in Belgium will present at this meeting holds some promise. 
I will end my discussion hoping to help some of those who will deal in their presen-
tation with ethical and social issues of heterotransplantation. About 5 years ago, I 
approached the NIH a month or 6 weeks before the Baby Fae case about the possibil-
ity of using chimpanzee livers for some of our very tiny biliary atresia patients for 
whom we could not find organs at that time. The rather extensive dialogue with peo-
ple at the NIH escalated to the Director and eventually it came to the Ethics Commit-
tee of that agency. The proposal was shelved by mutual agreement. By this time the 
Baby Fae case had come up quite unexpectedly. We realized what a firestorm of pu-
blicity and of condemnation further heterograft trials were apt to bring down on us. 
I was stunned when I saw the reaction to the Baby Fae case. In the earlier trials (mine 
and all of Reemtsma's) which are described in this volume, there was no particular 
sense of outrage. These earlier trails were not secret. Perhaps, the climate was differ-
ent. 
If we could have helped our patients, the prospect of receiving abuse would not 
have been a deterrent. There was another factor and that was a White Paper, issued 
by the NIH, at the end of a 5-year study. The conclusion published in Science was 
that only between 25 and 50 chimpanzees per year would be available in the United 
States for all of biomedical research, including that in the important fields of hepatitis 
and AIDS. The use of chimpanzees would further jeopardize an already endangered 
species, but without having an impact on the organ shortfall. We dropped the matter 
and have done nothing with it since. 
Acknowledgement 
Supported by Research Grants from the Veterans Administration and Project Grant 
No. OK 29961 from the National Institutes of Health, Bethesda, Maryland. 
References 
Starzl TE. Experience in Renal Transplantation. Philadelphia: WB Saunders Company, 1964; 
262-298. 
2 Porter KA. Pathological changes in transplanted kidneys. In: Starzl TE, Experience in Renal Trans-
plantation. Philadelphia: WB Saunders Company, 1964; 346-357. 
3 Starzl TE, Marchioro TL, Peters ON, Kirkpatrick CH, Wilson WEC, Porter KA, Rifkind D, Ogden 
DA, Hitchcock CR, Waddell WR. Renal heterotransplantation from baboon to man: experience with 
6 cases. Transplantation 1964: 2: 752-776. 
4 Wiener AS, Moor-Jankowski J. Blood groups in anthropoid apes and baboons. Science 1983; 142: 
67. 
28 
5 Starzl TE, Tzakis A, Makowka L, Banner B, Demetris A, Ramsey G, Duquesnoy R, Griffin M. The 
definition of ABO factors in transplantation: relation to other humoral antibody states. Transplant 
Proc 1987; 19: 4492--4497. 
Ii Terasaki PI, Marehioro TL. Starzl TE. In: Histocompatibility Testing. Washington DC. National 
Academy of Sciences. National Research Council, 1965; 83. 
7 Starzl TE (with the assistance ofCW Putnam). Experience in Hepatic Transplantation. Philadelphia: 
WB Saunders Company, 1969; 408--421. 
8 Porter KA. Pathology of the orthotopic homograft and heterograft. In: Starzl TE, cd. Experience 
in Hepatic Transplantation. Philadelphia: WB Saunders Company, 1969; 422--471. 
9 Auchincloss H Jr. Xenogeneic transplantation. A review. Transplantation \988; 46: \-20. 
10 Giles GR, Boehmig HF, Killy J, Amemiya H, Takagi H, Coburg AJ, Hathaway WE, Wilson CB, 
Dixon FJ. Starzl TE. Mechanism and modification ofrejcction ofheterografts between divergent spe-
cies. Transplant Proc 1970; 2: 522-537. 
II Starzl HE, Ishikawa M. Putnam CW, Porter KA, Pieache R, Husberg BS, Halgrimson CG, Schroter 
G. Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, 
resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc 1974; 6: 129 139. 
